# Belyntic

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/belyntic

- Industry: Chemicals
- Headquarters: Berlin, Germany
- Website: www.belyntic.com
- Total disclosed funding: $1.5M
- Latest round: Seed (Apr 16, 2019)
- Investors on record: 1

## About

Belyntic GmbH is a biotechnology company based in Berlin, Germany, specializing in the development of innovative T cell-inducing vaccines targeting viral and bacterial infectious diseases.Founded in 2018, Belyntic GmbH develops vaccines utilizing its T-Fender platform technology. The company has conducted two deals, with the most recent deal on November 8, 2021, involving a GRANT from the German Federal Ministry for Economic Affairs and Climate Action amounting to EUR 700,000. Total funds raised by Belyntic amount to EUR 1.3 mn. Oliver Reimann leads the company as Founder.Belyntic focuses on developing T cell-inducing vaccines designed to combat viral and bacterial infectious diseases. Its core offerings include a therapeutic and prophylactic vaccine portfolio that leverages self-adjuvant and self-aggregating synthetic long peptides, aimed at eliciting cellular immune responses. These vaccines particularly focus on protecting vulnerable populations, such as patients undergoing organ transplants, against infections like cytomegalovirus (CMV). Belyntic's products are targeted primarily in the European and North American markets.Belyntic operates a revenue model based on partnerships with healthcare providers and research institutions for developing its vaccine candidates. This model includes collaborations with pharmaceutical firms and healthcare systems, and revenue is expected to come from licensing agreements and supply contracts related to the T-Fender platform. Transactions typically involve upfront payments and milestone-based royalties, although specific pricing plans for the products are not disclosed.Following its most recent GRANT funding of EUR 700,000 on November 8, 2021, Belyntic plans to utilize this funding to support the preclinical phase of its vaccine candidate. The company is focused on launching upcoming products designed to enhance its portfolio and is exploring expansion into new markets across Europe and North America by 2023, reflecting the increasing demand for effective immunotherapies.

## Funding rounds

- Seed, Apr 16, 2019, $1.5M — High-Tech Gruenderfonds

## Investors

- High-Tech Gruenderfonds (https://capitalatlas.ai/funds/high-tech-gruenderfonds) — Seed